Spring Bank Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SBPH)

$11.92 +0.26 (+2.23 %)
(As of 02/22/2018 04:00 PM ET)
Previous Close$11.66
Today's Range$11.53 - $11.93
52-Week Range$7.95 - $18.93
Volume12,959 shs
Average Volume26,546 shs
Market Capitalization$152.32 million
P/E Ratio-4.52
Dividend YieldN/A
Beta0.75

About Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Spring Bank Pharmaceuticals logoSpring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases. The Company's SB 9200 selectively activates within infected cells the cellular proteins retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company is also developing a second SMNH product candidate, SB 11285, as an immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes (STING) pathway. The Company focuses on developing SB 9200 for the treatment of chronic hepatitis B virus (HBV).

Receive SBPH News and Ratings via Email

Sign-up to receive the latest news and ratings for SBPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SBPH
CUSIPN/A
Phone508-473-5993

Debt

Debt-to-Equity RatioN/A
Current Ratio12.99%
Quick Ratio13.00%

Price-To-Earnings

Trailing P/E Ratio-4.51936232805299
Forward P/E Ratio-5.25
P/E GrowthN/A

Sales & Book Value

Annual Sales$350,000.00
Price / Sales441.38
Cash FlowN/A
Price / CashN/A
Book Value$1.81 per share
Price / Book6.59

Profitability

Trailing EPS($2.58)
Net Income$-17,360,000.00
Net MarginsN/A
Return on Equity-73.58%
Return on Assets-46.80%

Miscellaneous

Employees20
Outstanding Shares12,960,000

Spring Bank Pharmaceuticals (NASDAQ:SBPH) Frequently Asked Questions

What is Spring Bank Pharmaceuticals' stock symbol?

Spring Bank Pharmaceuticals trades on the NASDAQ under the ticker symbol "SBPH."

How were Spring Bank Pharmaceuticals' earnings last quarter?

Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) announced its earnings results on Friday, April, 28th. The company reported ($0.47) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.47). View Spring Bank Pharmaceuticals' Earnings History.

Where is Spring Bank Pharmaceuticals' stock going? Where will Spring Bank Pharmaceuticals' stock price be in 2018?

5 brokerages have issued 1 year target prices for Spring Bank Pharmaceuticals' shares. Their forecasts range from $20.00 to $32.00. On average, they anticipate Spring Bank Pharmaceuticals' share price to reach $28.00 in the next year. View Analyst Ratings for Spring Bank Pharmaceuticals.

Who are some of Spring Bank Pharmaceuticals' key competitors?

When did Spring Bank Pharmaceuticals IPO?

(SBPH) raised $14 million in an IPO on Friday, May 6th 2016. The company issued 1,100,000 shares at a price of $12.00-$14.00 per share. Dawson James Securities served as the underwriter for the IPO.

Who owns Spring Bank Pharmaceuticals stock?

Spring Bank Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (6.36%), AXA (2.06%), Morse Asset Management Inc (1.13%), C WorldWide Group Holding A S (0.79%), Sphera Funds Management LTD. (0.57%) and Millennium Management LLC (0.39%). Company insiders that own Spring Bank Pharmaceuticals stock include David Arkowitz, Jonathan Freve, Kurt M Eichler, Martin J Driscoll and Nezam H Afdhal. View Institutional Ownership Trends for Spring Bank Pharmaceuticals.

Who sold Spring Bank Pharmaceuticals stock? Who is selling Spring Bank Pharmaceuticals stock?

Spring Bank Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Crestline Management LP, Deutsche Bank AG and C WorldWide Group Holding A S. View Insider Buying and Selling for Spring Bank Pharmaceuticals.

Who bought Spring Bank Pharmaceuticals stock? Who is buying Spring Bank Pharmaceuticals stock?

Spring Bank Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, Millennium Management LLC, Morse Asset Management Inc, Candriam Luxembourg S.C.A., AXA, Virtu Financial LLC, Wells Fargo & Company MN and BlackRock Inc.. Company insiders that have bought Spring Bank Pharmaceuticals stock in the last two years include David Arkowitz, Jonathan Freve, Kurt M Eichler, Martin J Driscoll and Nezam H Afdhal. View Insider Buying and Selling for Spring Bank Pharmaceuticals.

How do I buy Spring Bank Pharmaceuticals stock?

Shares of Spring Bank Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spring Bank Pharmaceuticals' stock price today?

One share of Spring Bank Pharmaceuticals stock can currently be purchased for approximately $11.92.

How big of a company is Spring Bank Pharmaceuticals?

Spring Bank Pharmaceuticals has a market capitalization of $152.32 million and generates $350,000.00 in revenue each year. The company earns $-17,360,000.00 in net income (profit) each year or ($2.58) on an earnings per share basis. Spring Bank Pharmaceuticals employs 20 workers across the globe.

How can I contact Spring Bank Pharmaceuticals?

Spring Bank Pharmaceuticals' mailing address is 86 SOUTH STREET, HOPKINTON MA, 01748. The company can be reached via phone at 508-473-5993.


MarketBeat Community Rating for Spring Bank Pharmaceuticals (SBPH)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  80 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  157
MarketBeat's community ratings are surveys of what our community members think about Spring Bank Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Spring Bank Pharmaceuticals (NASDAQ:SBPH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.802.802.75
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $28.00$27.25$27.25$26.33
Price Target Upside: 138.30% upside60.11% upside60.11% upside119.63% upside

Spring Bank Pharmaceuticals (NASDAQ:SBPH) Consensus Price Target History

Price Target History for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Spring Bank Pharmaceuticals (NASDAQ:SBPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/21/2018Cantor FitzgeraldReiterated RatingOverweight -> Overweight$29.00 -> $32.00LowView Rating Details
11/6/2017Chardan CapitalReiterated RatingBuyN/AView Rating Details
11/6/2017B. RileyInitiated CoverageBuy -> Buy$30.00N/AView Rating Details
8/7/2017Dawson JamesReiterated RatingBuyLowView Rating Details
5/19/2017JMP SecuritiesInitiated CoverageMkt Outperform -> Market Perform$20.00MediumView Rating Details
8/19/2016William BlairInitiated CoverageOutperform$26.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Spring Bank Pharmaceuticals (NASDAQ:SBPH) Earnings History and Estimates Chart

Earnings by Quarter for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Spring Bank Pharmaceuticals (NASDAQ SBPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017Q3 2017($0.46)($0.39)ViewN/AView Earnings Details
7/31/2017Q2 2017($0.48)($0.54)ViewN/AView Earnings Details
4/28/20173/31/2017($0.47)($0.47)ViewN/AView Earnings Details
2/15/2017Q4 2016($0.61)($0.51)ViewN/AView Earnings Details
10/31/2016Q3 2016($0.59)($0.53)ViewN/AView Earnings Details
8/1/2016Q2 2016($0.62)$0.07 millionViewN/AView Earnings Details
6/15/2016Q1 2016($1.11)$0.28 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Spring Bank Pharmaceuticals (NASDAQ:SBPH) Earnings Estimates

2018 EPS Consensus Estimate: ($2.70)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.90)($0.46)($0.68)
Q2 20182($0.90)($0.45)($0.68)
Q3 20182($0.91)($0.44)($0.68)
Q4 20182($0.91)($0.43)($0.67)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Spring Bank Pharmaceuticals (NASDAQ:SBPH)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Spring Bank Pharmaceuticals (NASDAQ SBPH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 17.60%
Institutional Ownership Percentage: 29.08%
Insider Trades by Quarter for Spring Bank Pharmaceuticals (NASDAQ:SBPH)
Institutional Ownership by Quarter for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Spring Bank Pharmaceuticals (NASDAQ SBPH) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/14/2017Martin J DriscollInsiderBuy1,000$14.84$14,840.0055,400View SEC Filing  
8/4/2017David ArkowitzDirectorBuy2,500$12.24$30,600.0017,086View SEC Filing  
8/3/2017Martin J DriscollInsiderBuy2,000$12.36$24,720.0053,400View SEC Filing  
6/27/2017Kurt M EichlerDirectorBuy76,923$13.00$999,999.00582,533View SEC Filing  
3/7/2017Martin J DriscollInsiderBuy2,000$9.44$18,880.0052,400View SEC Filing  
2/23/2017Kurt M EichlerDirectorBuy1,200$8.76$10,512.00505,610View SEC Filing  
12/15/2016Martin J DriscollInsiderBuy2,000$8.50$17,000.0050,400View SEC Filing  
11/30/2016Martin J DriscollInsiderBuy2,000$7.98$15,960.0048,400View SEC Filing  
11/9/2016Kurt M EichlerDirectorBuy7,000$8.69$60,830.00437,990View SEC Filing  
11/9/2016Martin J DriscollInsiderBuy2,000$8.84$17,680.0024,500View SEC Filing  
9/19/2016Kurt M EichlerDirectorBuy1,996$12.50$24,950.00429,644View SEC Filing  
9/14/2016Kurt M EichlerDirectorBuy514$12.50$6,425.00428,994View SEC Filing  
9/13/2016Kurt M EichlerDirectorBuy490$12.50$6,125.00428,480View SEC Filing  
9/9/2016Nezam H AfdhalInsiderBuy2,400$12.50$30,000.0040,150View SEC Filing  
9/2/2016Martin J DriscollInsiderBuy1,000$11.75$11,750.0022,500View SEC Filing  
8/30/2016Martin J DriscollInsiderBuy1,000$12.41$12,410.0021,500View SEC Filing  
8/24/2016Nezam H AfdhalInsiderBuy2,000$11.92$23,840.0037,300View SEC Filing  
8/23/2016Jonathan FreveCFOBuy1,000$10.74$10,740.002,000View SEC Filing  
8/23/2016Kurt M EichlerDirectorBuy3,000$10.73$32,190.00427,990View SEC Filing  
8/22/2016Martin J DriscollInsiderBuy2,000$11.43$22,860.0019,500View SEC Filing  
8/16/2016Nezam H AfdhalInsiderBuy1,900$11.43$21,717.0035,650View SEC Filing  
8/12/2016Nezam H AfdhalInsiderBuy2,600$11.33$29,458.0033,850View SEC Filing  
8/9/2016Martin J DriscollInsiderBuy2,000$11.03$22,060.0015,500View SEC Filing  
8/4/2016Jonathan FreveCFOBuy1,000$9.75$9,750.001,000View SEC Filing  
8/4/2016Martin J DriscollInsiderBuy2,000$9.96$19,920.0013,500View SEC Filing  
5/11/2016Kurt M EichlerDirectorBuy41,666$12.00$499,992.00423,990View SEC Filing  
5/11/2016Martin J DriscollCEOBuy12,500$12.00$150,000.0012,500View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Spring Bank Pharmaceuticals (NASDAQ SBPH) News Headlines

Source:
DateHeadline
Spring Bank Pharmaceuticals Inc Forecasted to Post FY2022 Earnings of $0.55 Per Share (SBPH)Spring Bank Pharmaceuticals Inc Forecasted to Post FY2022 Earnings of $0.55 Per Share (SBPH)
www.americanbankingnews.com - February 22 at 4:34 PM
Spring Bank Pharmaceuticals (SBPH) Price Target Increased to $32.00 by Analysts at Cantor FitzgeraldSpring Bank Pharmaceuticals (SBPH) Price Target Increased to $32.00 by Analysts at Cantor Fitzgerald
www.americanbankingnews.com - February 21 at 2:44 PM
Spring Bank Pharmaceuticals, Inc. to Host Earnings CallSpring Bank Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - February 21 at 10:34 AM
Spring Bank Pharmaceuticals Inc (SBPH) Given Consensus Rating of "Buy" by BrokeragesSpring Bank Pharmaceuticals Inc (SBPH) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 14 at 11:00 AM
Spring Bank Pharmaceuticals Inc (SBPH) Receives Average Recommendation of "Buy" from AnalystsSpring Bank Pharmaceuticals Inc (SBPH) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 20 at 8:08 AM
Spring Bank Strengthens Management Team to Enhance OperationsSpring Bank Strengthens Management Team to Enhance Operations
finance.yahoo.com - January 9 at 10:41 AM
Spring Bank Pharmaceuticals Inc (SBPH) Expected to Announce Earnings of -$0.55 Per ShareSpring Bank Pharmaceuticals Inc (SBPH) Expected to Announce Earnings of -$0.55 Per Share
www.americanbankingnews.com - January 8 at 5:04 PM
 Brokerages Anticipate Spring Bank Pharmaceuticals Inc (SBPH) Will Announce Earnings of -$0.55 Per Share Brokerages Anticipate Spring Bank Pharmaceuticals Inc (SBPH) Will Announce Earnings of -$0.55 Per Share
www.americanbankingnews.com - December 23 at 9:18 AM
 Brokerages Expect Spring Bank Pharmaceuticals Inc (SBPH) Will Post Earnings of -$0.53 Per Share Brokerages Expect Spring Bank Pharmaceuticals Inc (SBPH) Will Post Earnings of -$0.53 Per Share
www.americanbankingnews.com - December 5 at 3:30 PM
Spring Bank Pharmaceuticals (SBPH) Rating Lowered to Sell at ValuEngineSpring Bank Pharmaceuticals (SBPH) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - December 2 at 6:16 PM
Spring Bank Pharmaceuticals, Inc. (SBPH) Given Average Recommendation of "Buy" by BrokeragesSpring Bank Pharmaceuticals, Inc. (SBPH) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - December 1 at 4:30 PM
Spring Bank Pharmaceuticals (SBPH) and PTC Therapeutics (PTCT) Critical ContrastSpring Bank Pharmaceuticals (SBPH) and PTC Therapeutics (PTCT) Critical Contrast
www.americanbankingnews.com - November 30 at 1:28 AM
Spring Bank Pharmaceuticals Announces Positive Top-Line Results from the Second Cohort of Part A of the Phase 2 ACHIEVE TrialSpring Bank Pharmaceuticals Announces Positive Top-Line Results from the Second Cohort of Part A of the Phase 2 ACHIEVE Trial
finance.yahoo.com - November 18 at 11:38 AM
Zacks: Brokerages Anticipate Spring Bank Pharmaceuticals, Inc. (SBPH) to Post -$0.53 Earnings Per ShareZacks: Brokerages Anticipate Spring Bank Pharmaceuticals, Inc. (SBPH) to Post -$0.53 Earnings Per Share
www.americanbankingnews.com - November 17 at 9:30 PM
Spring Bank Pharmaceuticals, Inc. (SBPH) Given a $29.00 Price Target by Cantor Fitzgerald AnalystsSpring Bank Pharmaceuticals, Inc. (SBPH) Given a $29.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - November 16 at 10:38 AM
Analysts Set Expectations for Spring Bank Pharmaceuticals, Inc.s FY2017 Earnings (SBPH)Analysts Set Expectations for Spring Bank Pharmaceuticals, Inc.'s FY2017 Earnings (SBPH)
www.americanbankingnews.com - November 8 at 11:04 AM
Spring Bank to Present at Piper Jaffray’s 29th Annual Healthcare ConferenceSpring Bank to Present at Piper Jaffray’s 29th Annual Healthcare Conference
finance.yahoo.com - November 7 at 9:58 AM
Spring Bank Pharmaceuticals, Inc. (SBPH) Receives Consensus Recommendation of "Buy" from AnalystsSpring Bank Pharmaceuticals, Inc. (SBPH) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 6 at 10:46 AM
William Blair Weighs in on Spring Bank Pharmaceuticals, Inc.s FY2017 Earnings (SBPH)William Blair Weighs in on Spring Bank Pharmaceuticals, Inc.'s FY2017 Earnings (SBPH)
www.americanbankingnews.com - November 6 at 2:54 AM
Head to Head Review: Spring Bank Pharmaceuticals (SBPH) versus Its PeersHead to Head Review: Spring Bank Pharmaceuticals (SBPH) versus Its Peers
www.americanbankingnews.com - November 3 at 9:14 PM
Spring Bank Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial and Operational ResultsSpring Bank Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial and Operational Results
finance.yahoo.com - October 31 at 9:08 AM
Spring Bank Pharmaceuticals Announces Additional Inarigivir (formerly SB 9200) Results from the ACHIEVE Trial in HBV Patients at AASLD ConferenceSpring Bank Pharmaceuticals Announces Additional Inarigivir (formerly SB 9200) Results from the ACHIEVE Trial in HBV Patients at AASLD Conference
finance.yahoo.com - October 20 at 4:57 PM
Critical Comparison: Summit Therapeutics PLC (SMMT) & Spring Bank Pharmaceuticals (SBPH)Critical Comparison: Summit Therapeutics PLC (SMMT) & Spring Bank Pharmaceuticals (SBPH)
www.americanbankingnews.com - October 15 at 10:26 PM
Financial Analysis: Spring Bank Pharmaceuticals (SBPH) & Its CompetitorsFinancial Analysis: Spring Bank Pharmaceuticals (SBPH) & Its Competitors
www.americanbankingnews.com - October 14 at 6:08 AM
Spring Bank Pharmaceuticals Announces Presentation of Positive Preclinical Data on SB 11285 at the 2017 AACR Conference on Tumor Immunology and ImmunotherapySpring Bank Pharmaceuticals Announces Presentation of Positive Preclinical Data on SB 11285 at the 2017 AACR Conference on Tumor Immunology and Immunotherapy
finance.yahoo.com - October 6 at 8:51 AM
Spring Bank Pharmaceuticals Announces Two Presentations at the 2017 AASLD Conference in Washington, D.C.Spring Bank Pharmaceuticals Announces Two Presentations at the 2017 AASLD Conference in Washington, D.C.
finance.yahoo.com - October 6 at 8:51 AM
ROTY Volume 1 Edition 33: New Leadership In The Model Account, Changes To Format And TradesROTY Volume 1 Edition 33: New Leadership In The Model Account, Changes To Format And Trades
seekingalpha.com - September 29 at 11:15 AM
William Blair Weighs in on Spring Bank Pharmaceuticals, Inc.s Q1 2018 Earnings (SBPH)William Blair Weighs in on Spring Bank Pharmaceuticals, Inc.'s Q1 2018 Earnings (SBPH)
www.americanbankingnews.com - September 29 at 8:48 AM
Financial Survey: Spring Bank Pharmaceuticals (SBPH) versus AveXis (AVXS)Financial Survey: Spring Bank Pharmaceuticals (SBPH) versus AveXis (AVXS)
www.americanbankingnews.com - September 29 at 6:42 AM
Spring Bank Pharmaceuticals Announces a Poster Presentation of its lead STING Agonist, SB 11285, at the 2017 AACR Conference on Tumor Immunology and Immunotherapy in Boston, MASpring Bank Pharmaceuticals Announces a Poster Presentation of its lead STING Agonist, SB 11285, at the 2017 AACR Conference on Tumor Immunology and Immunotherapy in Boston, MA
finance.yahoo.com - September 20 at 8:44 AM
Chardan Capital Reaffirms Buy Rating for Spring Bank Pharmaceuticals, Inc. (SBPH)Chardan Capital Reaffirms Buy Rating for Spring Bank Pharmaceuticals, Inc. (SBPH)
www.americanbankingnews.com - September 20 at 6:26 AM
Insider Buying: Spring Bank Pharmaceuticals, Inc. (SBPH) Insider Acquires 1,000 Shares of StockInsider Buying: Spring Bank Pharmaceuticals, Inc. (SBPH) Insider Acquires 1,000 Shares of Stock
www.americanbankingnews.com - September 14 at 11:58 PM
Spring Bank Pharmaceuticals: Could SB 9200 ACHIEVE Greatness?Spring Bank Pharmaceuticals: Could SB 9200 ACHIEVE Greatness?
seekingalpha.com - September 13 at 8:49 AM
Spring Bank to Present at the Cantor Fitzgerald Global Healthcare ConferenceSpring Bank to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 13 at 8:49 AM
ROTY Volume 1 Edition 27: Spring Bank And Anaptysbio Making Moves Higher + A New Pilot PurchaseROTY Volume 1 Edition 27: Spring Bank And Anaptysbio Making Moves Higher + A New Pilot Purchase
seekingalpha.com - September 6 at 8:00 AM
Spring Bank to Present Additional Data from the First Cohort of its Ongoing SB 9200 ACHIEVE Clinical Trial at the 2017 International HBV Meeting in Washington D.C.Spring Bank to Present Additional Data from the First Cohort of its Ongoing SB 9200 ACHIEVE Clinical Trial at the 2017 International HBV Meeting in Washington D.C.
finance.yahoo.com - August 29 at 7:33 AM
FY2017 EPS Estimates for Spring Bank Pharmaceuticals, Inc. Lowered by Cantor Fitzgerald (SBPH)FY2017 EPS Estimates for Spring Bank Pharmaceuticals, Inc. Lowered by Cantor Fitzgerald (SBPH)
www.americanbankingnews.com - August 28 at 2:30 AM
BRIEF-Spring Bank Pharmaceuticals may offer and sell shares of up to $50 mln common stockBRIEF-Spring Bank Pharmaceuticals may offer and sell shares of up to $50 mln common stock
www.reuters.com - August 19 at 7:17 AM
 Brokerages Expect Spring Bank Pharmaceuticals, Inc. (SBPH) to Announce -$0.46 EPS Brokerages Expect Spring Bank Pharmaceuticals, Inc. (SBPH) to Announce -$0.46 EPS
www.americanbankingnews.com - August 14 at 4:20 AM
Spring Bank Pharmaceuticals: A Run-Up Into Year-EndSpring Bank Pharmaceuticals: A Run-Up Into Year-End
seekingalpha.com - August 14 at 3:07 AM
Spring Bank Pharmaceuticals, Inc. (SBPH) Earns "Buy" Rating from Dawson JamesSpring Bank Pharmaceuticals, Inc. (SBPH) Earns "Buy" Rating from Dawson James
www.americanbankingnews.com - August 12 at 6:34 AM
Spring Bank Pharmaceuticals, Inc. (SBPH) Director David Arkowitz Purchases 2,500 SharesSpring Bank Pharmaceuticals, Inc. (SBPH) Director David Arkowitz Purchases 2,500 Shares
www.americanbankingnews.com - August 7 at 8:02 PM
Martin J. Driscoll Buys 2,000 Shares of Spring Bank Pharmaceuticals, Inc. (SBPH) StockMartin J. Driscoll Buys 2,000 Shares of Spring Bank Pharmaceuticals, Inc. (SBPH) Stock
www.americanbankingnews.com - August 3 at 4:34 PM
William Blair Research Analysts Reduce Earnings Estimates for Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH)William Blair Research Analysts Reduce Earnings Estimates for Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH)
www.americanbankingnews.com - August 3 at 7:40 AM
Spring Bank Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial and Operational ResultsSpring Bank Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial and Operational Results
finance.yahoo.com - August 1 at 6:12 AM
Spring Bank Pharmaceuticals, Inc. to Post FY2017 Earnings of ($1.89) Per Share, Cantor Fitzgerald Forecasts (SBPH)Spring Bank Pharmaceuticals, Inc. to Post FY2017 Earnings of ($1.89) Per Share, Cantor Fitzgerald Forecasts (SBPH)
www.americanbankingnews.com - July 24 at 8:19 AM
Spring Bank Pharmaceuticals, Inc. (SBPH) Given Average Recommendation of "Buy" by AnalystsSpring Bank Pharmaceuticals, Inc. (SBPH) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 19 at 10:10 PM
Cantor Fitzgerald Initiates Coverage on Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH)Cantor Fitzgerald Initiates Coverage on Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH)
www.americanbankingnews.com - July 19 at 9:50 PM
BRIEF-Spring Bank Pharmaceuticals announces clinical trial collaboration with Gilead Sciences for clinical study examining SB 9200BRIEF-Spring Bank Pharmaceuticals announces clinical trial collaboration with Gilead Sciences for clinical study examining SB 9200
www.reuters.com - July 11 at 7:25 AM
Spring Bank Announces Collaboration with Gilead for Hepatitis B (HBV) Phase 2 Study Exploring Combination Treatment of SB 9200 and Vemlidy®Spring Bank Announces Collaboration with Gilead for Hepatitis B (HBV) Phase 2 Study Exploring Combination Treatment of SB 9200 and Vemlidy®
finance.yahoo.com - July 11 at 7:25 AM

SEC Filings

Spring Bank Pharmaceuticals (NASDAQ:SBPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Spring Bank Pharmaceuticals (NASDAQ SBPH) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.